# Moffitt Cancer Center Support Grant

> **NIH NIH P30** · H. LEE MOFFITT CANCER CTR & RES INST · 2020 · $99,999

## Abstract

PROJECT SUMMARY
The H. Lee Moffitt Cancer Center & Research Institute (MCC) continues its ambitious trajectory of innovative
cancer research and translation to benefit the gulf coast region of Florida and beyond. As a free-standing
501(c)3 not-for-profit institution with the sole purpose “to contribute to the prevention and cure of cancer,” all
research funding ($71.8M), publications (2,430), and clinical research (>1,600 interventional accruals/ year)
are cancer focused. Research and clinical space has expanded dramatically since the last renewal to more
than 2 million square feet, and patient clinical volume places MCC among the largest Centers in the United
States. MCC has benefitted from recent, ongoing annual state legislature funding of approximately $25 million,
in addition to more than $39 million of annual institutional research support. The 142 MCC members span the
basic, clinical, and population sciences. They are organized into five highly collaborative, multidisciplinary
programs with exceptional levels of intra- (35%) and inter-programmatic (18%) publications. Under the
leadership of Dr. Thomas Sellers, the third MCC Director, a Research Strategic Plan (RSP) was developed
and implemented for “Moffitt 3.0.” Four of six Associate Center Directors are new; and new leaders have been
appointed in every program, with bold goals and specific aims. Two of the 13 shared resources have been
significantly restructured (Chemical Biology, Molecular Genomics), and one new resource created
(Collaborative Data Services) to better meet the changing needs of MCC scientists. Implementation of the
strategic plan has been bolstered by substantial institutional investment, especially in basic science,
immunotherapy, and clinical research infrastructure, including the recruitment of 45 new faculty members, of
whom 32 are CCSG members. MCC is a leader in immunotherapy, and more than 40% of overall clinical trial
accrual is to investigator-initiated studies. MCC population scientists initiated significant new efforts in cancer
prevention and outcomes that include vaccines, tobacco cessation, and health disparities. This is particularly
true in the unique cancer problems in the catchment area – notably lung cancer, melanoma, and HPV-
prevention. MCC's Total Cancer Care protocol, the ground-breaking research strategy to realize the promise
of personalized medicine, has continued to thrive, resulting in dramatic utilization of the Tissue Core and the
formation of the Oncology Research Information Exchange Network (ORIEN) that now includes eleven cancer
centers across the nation, with several more poised to join the consortium this year. MCC requests funding for:
five scientific programs, 13 shared resources, two clinical research components, planning and evaluation,
administration, leadership, four staff investigators, and developmental funds. CCSG funds are leveraged more
than 10-fold with institutional resources to maximize impact on cancer prevention, treat...

## Key facts

- **NIH application ID:** 10243602
- **Project number:** 3P30CA076292-22S5
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** John L. Cleveland
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $99,999
- **Award type:** 3
- **Project period:** 1998-02-18 → 2022-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10243602

## Citation

> US National Institutes of Health, RePORTER application 10243602, Moffitt Cancer Center Support Grant (3P30CA076292-22S5). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10243602. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*